FOUR DRUGS / DIFFERENT ILLNESSES
What makes the drug comparisons fair or unfair?
Scientists developed these medicines for different jobs in the body, then tested different illnesses. Your answer depends on the patients, their usual care, and the health changes the researchers counted.
Why can’t one medicine be called best for everyone?
Scientists designed the four drugs to change different functions in the body. Their later tests asked different questions, so one overall winner wouldn't answer your health question.
Thymosin alpha-1 affects immune defenses, with mixed findings during life-threatening infection. Semaglutide and tirzepatide act after meals, with large studies that include a direct comparison of weight loss.
Bremelanotide, also called PT-141, changes brain activity connected with sexual interest. Approval concerns a particular desire loss that causes distress in women whose periods haven't ended.
For your comparison, ask which patients were tested and which health changes were counted. The other care patients received affects what a new treatment had to improve on.
Deciding treatment by chance makes groups fairer to compare than examining care doctors already chose. Hiding treatment names also helps limit changes in reports caused by people's expectations.
A large, careful negative study can outweigh an earlier small study that raised hope. Your judgment also needs the country's approved uses and the care given in the study.
Which patients, results, and concerns does each study cover?
| your question | Thymosin Alpha-1 | Semaglutide | Tirzepatide | PT-141 / Bremelanotide |
|---|---|---|---|---|
| What does the drug change? | Helps immune defenses act and restrain inflammation [6]. | copies GLP-1, a hormone released after food. | copies GIP and GLP-1, hormones that help control blood sugar after food [13]. | Changes activity in brain cells involved in desire [18]. |
| Which people took part? | People with severe infection or COVID-19; reviews also examined cancer care. | People with heart disease, excess weight, or kidney disease together with type 2 diabetes. | People with excess weight or type 2 diabetes. | Women distressed by lost desire before their periods ended through menopause. |
| What did researchers count? | deaths during a short follow-up [1]. | Separate tests of serious kidney problems, heart problems, and weight [9][10][11]. | Weight and blood sugar over time [8][15][16]. | Desire and distress from low desire [19]. |
| How strong were the tests? | many years of studies; the strongest recent infection test didn't show fewer deaths [1]. | Large studies checking several different health problems. | Large phase 3 tests, which check treatment in many people, plus direct drug comparisons. | Phase 3 treatment tests, followed by longer observation with treatment names known [19][20]. |
| Where does approval apply? | Several countries approve the medicine; the United States doesn't [2]. | Prescription medicine; approved uses vary across countries. | Prescription medicine; approved uses vary across countries [13]. | US approval concerns a specific loss of desire in women before menopause [21]. |
| What concern belongs beside the benefit? | sore or red shot sites; the main infection test didn't prove saved lives [1]. | stomach, bowel, and gallbladder complaints; uncommon harms remain uncertain [12]. | stomach and bowel complaints; more gallbladder and related drainage-tube problems counted together [14][15]. | Nausea and temporary blood-pressure rises; approval covers a limited group [20][21]. |
Could the study patients have been much sicker than you?
TESTS studied adults with sepsis across 22 hospitals, using chance to decide treatment. Sepsis is damage from immune defenses set off by infection; thymosin alpha-1 didn't clearly improve short-term survival [1].
A smaller report looked back at severe COVID-19 care and found a hopeful treatment link [3]. Patients may have differed before treatment, so other explanations for that result remain possible.
Those studies involved different illnesses, times, and hospital care, affecting the chance of survival. You can't fairly add their percentages as though all patients had the same illness and care.
STEP 1 tested weight in adults who didn't have diabetes; SELECT required heart disease beforehand [11]. SELECT also excluded diabetes, limiting who its heart result can tell you about [10].
FLOW required type 2 diabetes alongside kidney disease that persisted in the same people [9]. Each semaglutide answer concerns that study's patients and the health problems researchers counted.
SURMOUNT-5 tested tirzepatide for weight in people with obesity but without type 2 diabetes [8]. SURPASS-2 instead tested people with type 2 diabetes, asking a different treatment question [16].
PT-141 phase 3 tests, large treatment studies, concerned distressed women before menopause with desire lost across partners and situations [19][21]. That approved problem differs from low desire only in certain circumstances or reports from other groups.
How can other care change a drug’s apparent benefit?
A placebo resembles the study treatment but lacks its active medicine. Comparing against placebo tests whether adding the drug helps beyond the care both groups receive.
A direct drug comparison instead asks which medicine does better within that particular test. You face more doubt when doctors chose treatment for patients who already differed.
SURMOUNT-5 compared tirzepatide with semaglutide for weight; SURPASS-2 tested weight and blood sugar in type 2 diabetes [8][16]. You get a clearer drug comparison from those tests than from unrelated studies.
When you compare separate studies, the patients may have different starting health and different usual care, even though each study uses chance to make its own treatment groups fairer to compare. Chance assignment balances groups within a study; it doesn't make patients in separate studies alike.
Treatment amounts, follow-up time, and knowing the drug's name can also affect findings. In severe infection, antibiotics and support for failing organs may already be helping patients.
The new drug must improve on that existing care to show a benefit. Different hospital care helps explain why an earlier hopeful infection test and later negative test disagreed [1][5].
Different results don't require you to assume that the researchers were dishonest. You need the illness, patients' usual care, and how researchers chose treatment clearly explained.
Why must serious health problems be counted separately from weight?
A fall in weight, a better blood test, and fewer deaths answer different questions. You can't use one result as proof that another health problem improved.
STEP 1 checked weight, SELECT checked serious heart trouble, and FLOW checked kidney-related problems [9][10][11]. The separate semaglutide tests let you ask about each health problem using evidence from relevant patients.
SURMOUNT-5 found a larger average weight change under tirzepatide than under semaglutide [8]. That finding doesn't prove that tirzepatide also protects the heart or kidneys better.
PT-141 studies measured women's reported sexual interest and distress, beyond a physical response [19]. Thymosin alpha-1's main severe-infection test counted deaths and didn't clearly find fewer deaths [1].
Some studies add several problems into a single count, as FLOW did with kidney problems and deaths [9]. A lower total doesn't prove that each separate problem fell by the same amount.
The tirzepatide review counted gallbladder problems together with bile-duct trouble and found an increase; bile ducts drain fluid toward the bowel [14]. Adding cases made that increase clearer, but smaller separate counts couldn't prove which kind increased.
Does approval prove every claimed benefit?
Approval means a health authority accepted evidence for a particular medicine and medical use. Your research bottle or a different use doesn't gain that approval from sharing the name.
A substance without approval may still act in the body without having proved a useful treatment. You need study findings to judge benefit, as well as official information about approval.
Several countries have approved thymosin alpha-1 as a medicine; US approval hasn't been granted [2]. That difference affects access, checks on manufacture, and how problems after treatment are followed.
Approved uses for the prescription drugs semaglutide and tirzepatide depend on country and date. PT-141's US label covers certain women and warns plainly about temporary blood-pressure rises [21].
Patient studies show what changed in their health, while official labels define approved uses and warnings. A study can't grant approval, and approval can't prove a benefit the study never tested.
Funding and differences in reporting problems can affect which findings are available to read. Those concerns call for careful reading, rather than dismissing results without examining what happened.